Alkermes plc
ALKS
Helyezés a részvények között
#2726
Alkermes plc, a biopharmaceutical company, engages in the research,... Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Részvényárfolyam
$41.39
Utolsó szinkronizálás: 2026-10-16
Piaci kapitalizáció
$6.94B
Változás (1 nap)
3.22%
Változás (1 év)
36.78%
Ország
IE
Kereskedés Alkermes plc (ALKS)
Kategória
Healthcare
EPS Alkermes plc (ALKS) részvényre
EPS June 2026 dátummal, TTM: $0.40
Alkermes plc legfrissebb pénzügyi jelentései és részvényára alapján a vállalat jelenlegi EPS mutatója (TTM) $0.40. 2023 végén a vállalat EPS mutatója $2.14 volt, növekedés a 2022 év EPS értékéhez, amely $-0.97 volt.
Alkermes plc EPS története 2000 és 2026 között
EPS minden év végén
| Év | EPS | Változtassa meg |
|---|---|---|
| 2026 (TTM) | $0.40 | -81.98% |
| 2024 | $2.22 | 3.74% |
| 2023 | $2.14 | -320.62% |
| 2022 | $-0.97 | 223.33% |
| 2021 | $-0.30 | -57.14% |
| 2020 | $-0.70 | -44.00% |
| 2019 | $-1.25 | 38.89% |
| 2018 | $-0.90 | -12.62% |
| 2017 | $-1.03 | -25.36% |
| 2016 | $-1.38 | -9.21% |
| 2015 | $-1.52 | 623.81% |
| 2014 | $-0.21 | -210.53% |
| 2013 | $0.19 | 0.00% |
| 2012 | $0.19 | -119.19% |
| 2011 | $-0.99 | 106.25% |
| 2010 | $-0.48 | 14.29% |
| 2009 | $-0.42 | -130.66% |
| 2008 | $1.37 | -17.47% |
| 2007 | $1.66 | 1,560.00% |
| 2006 | $0.10 | 150.00% |
| 2005 | $0.04 | -104.82% |
| 2004 | $-0.83 | -33.60% |
| 2003 | $-1.25 | -26.47% |
| 2002 | $-1.70 | 77.08% |
| 2001 | $-0.96 | 123.26% |
| 2000 | $-0.43 | 0.00% |
EPS hasonló cégek vagy versenytársak esetén
| Vállalat | EPS | EPS különbség | Ország |
|---|---|---|---|
| $17.32 | 4,230.00% |
US
|
|
| $-7.98 | -2,095.00% |
US
|
|
| $-5.29 | -1,422.50% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 6,835.00% |
NL
|
